<a href="https://www.fiercebiotech.com/biotech/chutes-ladders-former-fda-leader-takes-new-biotech-turn" hreflang="en">Chutes & Ladders—Former FDA leader takes new biotech Turn</a>
Stephen Hahn, former FDA commissioner, has joined Turn Therapeutics as the executive clinical and regulatory lead, focusing on the regulatory strategy for a topical eczema treatment. Meanwhile, Amgen is set to replace its CFO with former executive Thomas Dittrich, and Antag Therapeutics has appointed Philip Just Larson as its new CEO, reflecting significant leadership changes in the biotech industry.
The key insight for a professional tracking healthtech and biotech is the strategic move by Stephen Hahn, former FDA commissioner, to join Turn Therapeutics as the executive clinical and regulatory lead. This is particularly noteworthy as Hahn will leverage his regulatory expertise to guide Turn's eczema treatment, GX-03, through its phase 2 study. For investors and stakeholders in biotech, Hahn’s involvement could signal increased regulatory traction and potentially smoother FDA interactions, enhancing the company's credibility and appeal.